← Back to The Daily Signal
Supplements & Nootropics

A Urolithin A Trial Missed Its Main Goal. The Press Release Led With Something Else

Every clinical trial names its main question before it starts. That rule exists so nobody can run a study, look at twenty measurements and report whichever one moved. This small urolithin A trial is a neat example of why the rule matters.

Written by Sama Alabed · November 19, 2026

The short version

What was tested

Urolithin A is a compound the gut makes from polyphenols in foods such as pomegranate, and it is sold as a supplement for mitochondrial and muscle health. In this trial, 50 adults aged 40 to 64 with obesity were randomized to 1,000 mg of urolithin A a day or a placebo for four weeks. Forty three completed it.

A whole pomegranate with its crown, shown close up

A pomegranate. The gut makes urolithin A from polyphenols in foods like this one.

איתן פרמן

Illustrative. The trial used a 1,000 mg supplement, not pomegranate.

The registered primary outcome was flow mediated dilation, which measures how well an artery widens when blood flow increases, a common marker of blood vessel health.

What happened to the main question

Flow mediated dilation rose by 1.3 percent on urolithin A and 0.3 percent on placebo. The difference was not statistically significant: the estimate was 1.74 with a confidence interval running from minus 1.33 to 4.81, and P was .33. On its own main question, the trial found no clear effect.

MISSED

Primary: blood vessel function

1.3 percent versus 0.3 percent, P = .33.

UP

Secondary: brain oxygenation

One region, during a task.

SAME

Memory and task scores

No improvement.

50 adults aged 40 to 64 with obesity, 1,000 mg a day for 4 weeks, 43 completed.

What got the attention

Among the secondary measures, brain oxygenation in the left dorsolateral prefrontal cortex, a region involved in planning and attention, rose during a cognitive task, and that held up after the researchers corrected for multiple comparisons. A university press release a month later led with this brain blood flow finding, while also reporting that blood vessel function and memory test results did not improve significantly.

it is not the same as a benefit you would notice

The trial also measured whether people actually thought better. Memory and task scores did not improve. A change in blood oxygenation during a task is interesting physiology, but it is not the same as a benefit you would notice.

Honest caveat

Four weeks and 50 people is very small and very short for a vascular outcome, so a real but modest effect could have been missed. About three quarters of participants were women, and about one in five was taking a GLP-1 drug, which may have affected results. The secondary findings are worth testing again, not worth acting on.

What this means for you

If you take urolithin A for heart or blood vessel health, this trial does not support that use, though it is too small to rule it out. If you take it for focus or memory, the brain finding is a hint for future research, not evidence of a benefit.

The broader habit worth keeping: when a supplement study reaches you through a press release, look for the primary outcome first. If the headline is about something else, that tells you something.

Primary sources

  1. JAMA Network Open, published online October 9, 2026: urolithin A supplementation in middle aged adults with obesity, a randomized clinical trial, NCT05921266

Common questions

Did urolithin A improve blood vessel function?

Not significantly. Flow mediated dilation rose 1.3 percent on urolithin A and 0.3 percent on placebo, with P = .33, so the trial's main outcome was not met.

Did it improve memory?

No. Brain oxygenation in one region rose during a task, but memory and task scores did not improve.

Why does the primary outcome matter?

It is the question the trial was designed and powered to answer. Secondary findings are useful for future studies, but a trial that measures many things will find some changes by chance.

Continue readingMitochondria & LongevityNMN Just Became a Mass Market Gummy, and the Newest Meta Analysis Found No Metabolic BenefitVitafusion, now owned by Piping Rock, launched Vital NMN Gummies at 300 milligrams per serving behind a TikTok first Aging? Love It. campaign, right after the FDA reversed the rule that had excluded NMN from the supplement definition since 2022. A July 2026 meta analysis of 15 randomized trials found NMN safe short term, with no rise in adverse events or liver enzymes, but no significant effect on weight, blood sugar, HbA1c, or cholesterol.Read the storyRelated guideMitochondria HacksWhat actually supports cellular energy, which claims hold up, and where the evidence runs out.Read the guide
Urolithin AMitochondriaClinical TrialSupplementsLongevity

#UrolithinA#Mitochondria#ClinicalTrial#Supplements#Longevity

Stay Curious.

Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.